Cencora (NYSE:COR) Announces Earnings Results, Beats Estimates By $0.08 EPS

Cencora (NYSE:COR) posted its quarterly earnings data on Wednesday. The company reported $4.66 earnings per share for the quarter, beating the consensus estimate of $4.58 by $0.08, FiscalAI reports. The business had revenue of $88.35 billion for the quarter, compared to analysts’ expectations of $87.95 billion. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The business’s revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm posted $3.84 EPS.

Here are the key takeaways from Cencora’s conference call:

• Cencora reported fiscal 2026 adjusted operating income growth of 14% and adjusted diluted EPS of $17.97, up 12%. Adjusted free cash flow was $3.8 billion, and the company announced a 10% increase to its quarterly dividend.
• The company is consolidating specialty capabilities into a new segment, targeting long-term operating income growth in the mid-teens; its fiscal 2027 segment outlook is 18%–21%, including the OneOncology acquisition contribution. Cencora expects specialty distribution revenue to reach approximately $100 billion in fiscal 2027.
• Fiscal 2027 adjusted EPS guidance is $19.40–$19.75, representing 8%–10% growth, or 10%–12% excluding the assumed MWI-Covetrus merger impact. Management projects operating income growth of 8.5%–11% excluding businesses in Other, ahead of its long-term targets.
• Reported fiscal 2027 operating income growth guidance is 4%–6%, with businesses in Other expected to reduce growth by about five percentage points; the Pharmaceutical Distribution and Services segment is forecast to grow operating income just 2%–4%, partly due to a customer volume shift and foreign exchange. Adjusted free cash flow is expected to decline to approximately $3.5 billion from $3.8 billion.

Cencora Stock Up 3.7%

Shares of COR traded up $12.64 on Wednesday, hitting $353.14. 1,799,439 shares of the stock traded hands, compared to its average volume of 1,462,783. The company has a market capitalization of $67.39 billion, a PE ratio of 26.18, a P/E/G ratio of 1.73 and a beta of 0.58. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. The business has a 50 day simple moving average of $324.08 and a 200 day simple moving average of $317.45. Cencora has a one year low of $244.82 and a one year high of $377.54.

Key Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora reported adjusted Q4 EPS of $4.66, topping analyst estimates of about $4.58, while revenue of $88.4 billion also exceeded expectations. Revenue rose 5.5% year over year, and EPS increased from $3.84 a year earlier. The company also recorded its fifth consecutive earnings beat, according to the report. Article: Cencora Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Cencora raised its dividend, adding a shareholder-return positive alongside the earnings beat. The dividend increase amount was not provided in the article summary. Article: Cencora Q4 2026 Earnings: Fifth Straight Beat, Dividend Raised
• Neutral Sentiment: The company is realigning its organizational and reporting structure to strengthen execution and improve visibility. The strategic change may support focus over time, but no specific near-term financial impact was detailed. Article: Cencora Announces New Organizational and Reporting Structure

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on COR. UBS Group reduced their price target on Cencora from $430.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, October 16th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $330.00 target price on shares of Cencora in a research report on Tuesday, September 8th. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Evercore restated an “outperform” rating and issued a $350.00 price target (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Finally, Argus boosted their target price on Cencora from $340.00 to $380.00 and gave the stock a “buy” rating in a report on Tuesday, October 20th. Fourteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $368.38.

About Cencora

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.